While NuVasive shares lost 6.43 percent on a four-week basis, the shares are marginally negative as compared to the S&P 500 for the past week with a loss of 2.08 percent. The company has underperformed the index by 6.91 percent in the past four weeks.
The 52-week low of the share price is $31.35 and the percentage difference in the current price and the 52-week high is 9.04 percent, according to the report.
More articles on devices:
Smith & Nephew, Misonix, Precision Spine & more — 22 key notes
Smith & Nephew insider sells 11k+ shares
Wright Medical Group’s “neutral” rating reaffirmed by Zacks
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
